ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...

Nearly half of ACP subscribers were military families, according to a White House fact sheet. Older Americans, African Americans and Latinos have also relied on the ACP at higher rates.

After hours: February 4 at 6:19:49 PM EST ...

The company has a promising pipeline that includes ACP-101 for Prader-Willi Syndrome (PWS) and ACP-204 for Alzheimer's Disease Psychosis (ADP). Phase 3 trials for ACP-101 and Phase 2/3 trials for ...

We are also pleased to share updates on our R&D pipeline—both today and at our ... the last patient in the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome anticipated in the ...

This project has not set up a SECURITY.md file yet.